

# Request for Application

WiL Academy Singapore  
CAR-T Educational Internship



## Objective

This internship program focuses on providing in-depth training in the following areas:

- **Patient Selection:** Identifying suitable candidates for CAR-T cells therapy in adult patients.
- **CAR-T Process:** Understanding the CAR-T cells therapy mechanisms, administration, and logistics.
- **Side Effects Management:** Learning strategies for monitoring and managing potential adverse effects post-therapy.

The internship will allow participants to gain hands-on experience with the CAR-T cell therapy journey, from T-cell collection to patient recovery. Participants will also observe the clinical decision-making process, including tumour board discussions, and visit key medical units involved in CAR-T therapy administration.

## Background & Program Overview

### Organisation Overview

WiL is committed to supporting and advocating for greater female representation and leadership in the field of lymphoma. Our objectives include empowering female voices, working to address gender disparities, and providing career development opportunities for women. We aim to achieve this through our core initiatives of education, career development, networking and advocacy.

### Program Information

The WiL Academy is a pioneering educational initiative aimed at promoting health equity in the rapidly evolving field of CAR-T therapy. This program offers an opportunity for female clinicians from around the world to advance their knowledge in CAR-T therapy, a cutting-edge treatment for lymphoma. Singapore is a hub for access to CAR-T cells in Southeast Asia.

The WiL Academy program in Singapore can serve as a central training site for female clinicians from Southeast Asia, where access to advanced therapies like CAR-T may be limited or emerging. The first prototype of the WiL Academy CAR-T Educational Internship is developed in collaboration with The National University Cancer Institute Singapore (NCIS), one of the leading centres in South East Asia for CAR-T therapy with expertise in patient selection, treatment administration, and management of post-treatment side effects.

The internship will consist of two female clinicians attending at the same time and must be completed by the end of 2026. The program is structured in three phases:

- **Phase 1:** Review the main indications for CAR-T cells in both adults and pediatrics.
- **Phase 2:** (running concurrently with Phase 3): Follow the CAR-T cell journey, including T-cell collection, modification, lymphodepleting chemotherapy, CAR-T infusion, early recovery, and long-term recovery.
- **Phase 3:** Follow the patient's journey through pre-treatment evaluation, tumour board discussion, visits to the cellular therapy unit, hematology unit, and discussions with CAR-T clinical coordinators.

In addition, there will also be lectures and discussions to provide practical information to guide clinicians in setting up their CAR-T program.

Through this collaboration with the National University Cancer Institute Singapore (NCIS), the Singapore General Hospital, the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Advanced Cell Therapy and Research Institute (ACTRIS), the WiL Academy Singapore aims to leverage regional networks in Southeast Asia to support female clinicians in the field.

## Eligibility Criteria

---

Applicants must meet the following requirements:

- Be licensed physicians with experience in hematology or oncology.
- Preference will be given to female physicians currently working in CAR-T centers or those who plan to open a CAR-T center in the near future in South East Asia since the host hematology unit will be the Department of Haematology-Oncology, National Cancer Institute Singapore.
- Applicants must be part of a newly opened CAR-T center, or have the ambition to open a CAR-T center in the coming year.
- Submit a report highlighting the outcomes of the program 12 months after completion.
- Applicants should demonstrate a commitment to returning to their country of origin to implement knowledge and skills acquired.

## Application Process

To apply for the WiL Academy CAR-T Educational Internship, candidates must submit the following to [wil@lymphoma.org.au](mailto:wil@lymphoma.org.au) for review by a jury committee:

1. Curriculum Vitae (CV).
2. Cover Letter detailing your interest in CAR-T therapy, your current professional responsibilities, and why you believe you would be a good fit for the program.
3. A personal statement describing your aspirations, career goals, and your commitment to returning to your home institution to contribute to the field of CAR-T therapy, including submission of a report highlighting implementation achievements 12 months after program completion.
4. A letter of endorsement from your department head or supervisor, granting leave for the duration of the program and supporting your development during the internship.
5. A follow-up plan outlining how you will monitor CAR-T patients and the goals for patient treatment in the two years following the internship.

## Timeline

Application & program key dates:

Description	Date
Publication Date / Call for Application	Oct 1, 2025 - Dec 31, 2025
Application Deadline	Dec 31, 2025
Jury Review Process	Jan 1, 2026 - Jan 31, 2026
Candidate Selection Announcement	Feb 16, 2026
Program Start Date	Aug 31, 2026



**WOMEN***in*  
**LYMPHOMA**

Supported by  Lymphoma  
Australia

For more information about this program:

[www.womeninlymphoma.org](http://www.womeninlymphoma.org)

[wil@lymphoma.org.au](mailto:wil@lymphoma.org.au)